Puma Biotechnology, Inc.
PBYI
$6.07
$0.172.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.91% | -12.96% | 8.63% | 2.68% | -2.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.91% | -12.96% | 8.63% | 2.68% | -2.19% |
| Cost of Revenue | -9.70% | -34.56% | 11.67% | 6.71% | 2.75% |
| Gross Profit | 2.50% | -3.39% | 7.52% | 1.23% | -3.98% |
| SG&A Expenses | -11.62% | -16.86% | -22.44% | -14.17% | -10.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.23% | -15.25% | -3.81% | -2.28% | -1.42% |
| Operating Income | 20.45% | 1.62% | 135.86% | 40.03% | -6.91% |
| Income Before Tax | 48.47% | 25.33% | 319.97% | 93.35% | 6.29% |
| Income Tax Expenses | 175.61% | -525.61% | -558.28% | -628.11% | -670.45% |
| Earnings from Continuing Operations | 2.75% | 59.11% | 455.63% | 147.59% | 40.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.75% | 59.11% | 455.63% | 147.59% | 40.23% |
| EBIT | 20.45% | 1.62% | 135.86% | 40.03% | -6.91% |
| EBITDA | 15.45% | -2.95% | 79.88% | 23.95% | -8.25% |
| EPS Basic | 1.03% | 56.02% | 429.89% | 137.93% | 34.91% |
| Normalized Basic EPS | 46.05% | 19.49% | 278.38% | 79.21% | -0.52% |
| EPS Diluted | -0.62% | 59.60% | 462.82% | 145.34% | 37.38% |
| Normalized Diluted EPS | 44.56% | 19.36% | 281.99% | 80.15% | -0.30% |
| Average Basic Shares Outstanding | 2.77% | 2.92% | 3.03% | 3.12% | 3.22% |
| Average Diluted Shares Outstanding | 3.81% | 3.46% | 3.27% | 2.89% | 2.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |